Today Emergent BioSolutions (NYSE: EBS) recognizes the 10-year anniversary of the U.S. Food and Drug Administration (FDA) approval of NARCAN ® (naloxone HCl) Nasal Spray as the first FDA-approved ...

Emergent BioSolutions is rated Buy after a Q3 earnings beat, CEO turnaround progress, and improved financial outlook. Read ...

Emergent BioSolutions (NYSE: EBS) announced today that Dr. Louis W. Sullivan will retire from the company’s Board of Directors effective November 14 after 19 years of service to the company and its ...

In the whole history of the Orthodox Church in America, this has never been seen,” a priest said about the surge of young men ...

Sean Carlos Payne was sentenced to 35 years in federal prison on charges of sexual exploitation of a minor, among other ...

Emergent Media partnered with Pacifico® Clara to launch an always-on social content campaign spanning May through October, spotlighting iconic cultural and sporting events. Designed to engage Pacifico ...

Agios Pharmaceuticals (AGIO) stock falls as a late-stage trial for its lead drug mitapivat in sickle cell disease indicate a ...

(Reuters) -Federal Reserve Governor Stephen Miran said on Wednesday that easing financial firms' regulatory burden could ...

NYSE:EBS Earnings and Revenue History November 7th 2025 The Impact Of Unusual Items On Profit. To properly understand Emergent BioSolutions' profit results, we need to consider th ...

What Happened: Dayal's recent move involves selling 8,552 shares of Emergent BioSolutions. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Monday.

Several medical groups are pushing back on planned payment policy changes announced by Anthem Blue Cross Blue Shield, arguing ...

Agentic AI is not just an investment in technology with a fixed term replacement cycle. It can also be an employee, that ...